Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M), while Vanguard Information Technology Index Fund ETF trades at $117.29. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | VGT | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | — |
52-Week High | $16.14 | $125.77 |
52-Week Low | $5.48 | $83.59 |
Enterprise Value | $627.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
VGT trades at $115.58, down 2.12% on the day amid a neutral technical signal. The ETF's moving averages show bearish momentum, while oscillators are neutral. Recent news highlights strong 2026 performance against the S&P 500 and ongoing investor interest in tech ETFs, though fee comparisons with competitors like FTEC are noted. A 1:8 stock split occurred in April 2026, with a small dividend scheduled for June 2026.
Outlook remains tied to tech sector strength and AI-driven earnings, but risks include valuation sensitivity and sector volatility. The ETF's low expense ratio and broad diversification offer a cost-effective tech exposure, yet overlap costs and hyperscaler capex guidance in H2 2026 warrant monitoring for potential pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
